DGAP-News: MeVis Medical Solutions AG: Marcus Kirchhoff becomes sole Executive Board Member
DGAP-News: MeVis Medical Solutions AG / Key word(s): Personnel
MeVis Medical Solutions AG: Marcus Kirchhoff becomes sole Executive Board Member
07.05.2019 / 18:41
The issuer is solely responsible for the content of this announcement.
Bremen, May 7, 2019 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces a change in its Executive Board.
As of April 1, 2019, Marcus Kirchhoff has taken over as sole member of the Executive Board of MeVis Medical Solutions AG. Kirchhoff was appointed to the Executive Board in 2012 as CEO and, in addition to his previous activities in this function, will now also be responsible for oversight of Finance, Human Resources and IT activities.
The former Chief Financial Officer Dr. Robert Hannemann left the company at his own request and reached an agreement with the Supervisory Board on the premature termination of his mandate. The Executive Board and Supervisory Board would like to thank Dr. Hannemann for his dedicated work over more than 8 years.
"Dr. Robert Hannemann has played a decisive role in co-managing the company constructively and with great commitment. Especially during and after the takeover by the current majority shareholder, Varex Imaging Corporation, Dr. Hannemann made a significant contribution with his expertise and competence. On behalf of the entire Supervisory Board, I would also like to thank him personally for his years of untiring commitment," emphasized Kim Honeysett, Chairperson of the Supervisory Board. "We wish Dr. Hannemann all the best for the future. The management of MeVis Medical Solutions AG will now be led by Marcus Kirchhoff, as sole Executive Board member, and his experienced capable management team. We know and appreciate Mr. Kirchhoff from the good cooperation so far and look forward to a continued successful future of the company under his leadership."
************************************************************************
Contact:
Kirchhoff, Marcus / CEO
07.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
MeVis Medical Solutions AG |
|
Caroline-Herschel-Str. 1 |
|
28359 Bremen |
|
Germany |
Phone: |
+49 421 224 95 0 |
Fax: |
+49 421 224 95 999 |
E-mail: |
[email protected] |
Internet: |
http://www.mevis.de |
ISIN: |
DE000A0LBFE4 |
WKN: |
A0LBFE |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
808285 |
|
End of News |
DGAP News Service |
808285 07.05.2019
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
18,54 |
16,76 |
18,07 |
17,13 |
16,21 |
18,76 |
17,34 |
EBITDA1,2 |
9,18 |
7,60 |
8,25 |
5,97 |
4,77 |
7,99 |
3,99 |
EBITDA-Marge3 |
49,51 |
45,35 |
45,66 |
34,85 |
29,43 |
42,59 |
|
EBIT1,4 |
7,96 |
6,69 |
8,00 |
5,81 |
4,64 |
7,90 |
3,89 |
EBIT-Marge5 |
42,93 |
39,92 |
44,27 |
33,92 |
28,62 |
42,11 |
22,43 |
Jahresüberschuss1 |
5,62 |
7,17 |
8,07 |
5,70 |
4,55 |
7,79 |
4,92 |
Netto-Marge6 |
30,31 |
42,78 |
44,66 |
33,27 |
28,07 |
41,52 |
28,37 |
Cashflow1,7 |
7,32 |
5,52 |
6,55 |
2,89 |
9,13 |
4,86 |
5,85 |
Ergebnis je Aktie8 |
3,09 |
3,94 |
4,43 |
3,13 |
2,50 |
4,28 |
2,70 |
Dividende8 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
0,95 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: Deloitte
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
MeVis Med. Solutions |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A0LBFE |
25,200 |
Halten |
45,86 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
10,50 |
10,26 |
1,00 |
7,68 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,57 |
7,83 |
2,64 |
10,70 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,95 |
0,95 |
3,77 |
19.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
- |
27.05.2025 |
- |
30.01.2025 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
5,34% |
0,58% |
0,00% |
-5,26% |
|
|